November 27, 2014 5:57 PM ET

Healthcare Providers and Services

Company Overview of Dominion Diagnostics, LLC

Company Overview

Dominion Diagnostics, LLC, a medical laboratory, provides clinical quantitative urine drug testing, medication monitoring, and support services in the United States. The company provides services to clients in various medical specialties, including pain medicine, primary care, addiction treatment, behavioral health, psychiatry, and hospital systems. It offers laboratory testing services, such as customized profiles and reports for individual patient monitoring, clinical assistance in results interpretation, reagents and instruments, biological monitoring and adulteration testing, rapid results through multiple reporting avenues, long-term specimen storage, comprehensive medication monitoring...

211 Circuit Drive

North Kingstown, RI 02852

United States

Founded in 1997





Key Executives for Dominion Diagnostics, LLC

Chief Executive Officer
Co-Founder And President
Chief Operating Officer
Laboratory Director
Vice President of Addiction Services
Compensation as of Fiscal Year 2014.

Dominion Diagnostics, LLC Key Developments

Dominion Diagnostics, LLC Enters into Exclusive Agreement with LifeGen, Inc. for Genetic Testing and Research

Dominion Diagnostics, LLC has entered into an exclusive agreement with LifeGen Inc. for the licensing rights to patented genetic testing. Currently the two companies are involved in a research study aimed at validating the testing against the Addiction Severity Index (ASI) designed and marketed by Inflexxion Inc. The research results are on track to be released in the first quarter of 2013, and are expected to show that LifeGen's test is valuable in determining a patient's Genetic Addiction Risk Score (GARS), or relative predisposition in manifesting addictive behaviors. Approximately 400 patient subjects selected from addiction treatment facilities across the country are involved in the GARS analysis. The GARS analysis is set to investigate a panel of genes primarily involved in brain reward circuitry. For 30% of the human population (approximately 100 million people), genetics are a large factor in dopamine-driven addiction. This subset of the population carries the DRD2 Type A1 receptor gene which induces low dopamine brain function that results in the propensity for addictive cravings. The GARS test involves a number of reward genes and related polymorphisms which have significant impact on substance use disorders. LifeGen's Kenneth Blum, PhD is the primary investigator on the companies' current research. Blum is credited with the first known association of the dopamine D2 receptor (DRD2) gene with alcoholism and other addictive behaviors including drug addiction, smoking, overeating, gambling, and sex (Blum & Noble, JAMA, 1990).

Similar Private Companies By Industry

Company Name Region
Blue Cross and Blue Shield of North Carolina, Inc. United States
Chapman Medical Center, Inc. United States
Golden Valley Memorial Healthcare United States
Ball HealthCare Services, Inc. United States
Cardinal Health 106, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Dominion Diagnostics, LLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at